Trial Profile

A First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCARTM-T Cells Armed With MicAbodyTM Protein (ASP2802) Followed by Maintenance Booster Doses of the MicAbody Protein in Patients With CD20-Positive Relapsed or Refractory B-Cell Lymphomas

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASP 2802 (Primary)
Indications Anaplastic large cell lymphoma; B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Marginal zone B-cell lymphoma; Primary cutaneous anaplastic large cell lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Astellas Pharma

03 Jan 2025 According to ClinicalTrials.gov, The termination of the study was a business decision made by the sponsor
03 Jan 2025 Status changed from recruiting to discontinued.
28 Jun 2024 Planned End Date changed from 31 May 2031 to 31 Aug 2031.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com